Greenwich LifeSciences Inc Dossier
Qualitative Analysis
Business overview
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy designed to prevent breast cancer recurrences in patients who have previously undergone surgery. The company's lead product candidate is GLSI-100, which combines the GP2 transmembrane peptide with the immunoadjuvant GM-CSF. GP2 targets the HER2/neu protein, which is expressed in approximately 75% of breast cancers. Greenwich LifeSciences is currently advancing GLSI-100 through its global Phase III clinical trial, FLAMINGO-01, which is designed to evaluate safety and efficacy in HER2/neu positive breast cancer patients.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the global footprint of the Phase III FLAMINGO-01 trial evaluating GLSI-100 to prevent breast cancer recurrences, targeting up to 150-200 global sites across the US and Europe.
Expected impact: Aims to generate robust safety and efficacy data across a diverse patient population to support regulatory filings for marketing approval.
Utilizing an ATM common stock financing vehicle to raise capital directly in the trading market to fund clinical operations while maintaining a lean corporate structure.
Expected impact: Provides a flexible capital bridge to fund the FLAMINGO-01 trial and potentially transition to non-dilutive strategic partnerships or debt/royalty financing.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations